Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial
- 16 April 2003
- journal article
- clinical trial
- Published by Wiley in BJU International
- Vol. 91 (7), 608-612
- https://doi.org/10.1046/j.1464-410x.2003.04167.x
Abstract
To present the results (to January 1996, the end of blinded treatment) of the Nutritional Prevention of Cancer (NPC) Trial, a randomized trial of selenium (200 micro g daily) designed to test the hypothesis that selenium supplementation (SS) could reduce the risk of recurrent nonmelanoma skin cancer among 1312 residents of the Eastern USA. Original secondary analyses of the NPC to 1993 showed striking inverse associations between SS and prostate cancer incidence. A subsequent report revealed that this effect was accentuated among men with the lowest baseline plasma selenium concentrations. The effects of treatment overall and within subgroups of baseline prostate-specific antigen (PSA) and plasma selenium concentrations were examined using incidence rate ratios and Cox proportional hazards models. SS continued to significantly reduce the overall incidence (relative risk and 95% confidence interval) of prostate cancer (0.51, 0.29-0.87). The protective effect of SS appeared to be confined to those with a baseline PSA level of <or= 4 ng/mL (0.35, 0.13-0.87), although the interaction of baseline PSA and treatment was not statistically significant. Participants with baseline plasma selenium concentrations only in the lowest two tertiles (< 123.2 ng/mL) had significant reductions in prostate cancer incidence. A significant interaction between baseline plasma selenium and treatment was detected. To the end of the blinded treatment the NPC trial continued to show a significant protective effect of SS on the overall incidence of prostate cancer, although the effect was restricted to those with lower baseline PSA and plasma selenium concentrations.Keywords
This publication has 19 references indexed in Scilit:
- PLASMA SELENIUM LEVEL BEFORE DIAGNOSIS AND THE RISK OF PROSTATE CANCER DEVELOPMENTJournal of Urology, 2001
- SELECT: THE NEXT PROSTATE CANCER PREVENTION TRIALJournal of Urology, 2001
- Staging prostate cancerMicroscopy Research and Technique, 2000
- Structure-Expression Relationships of the 15-kDa Selenoprotein GenePublished by Elsevier BV ,2000
- Evaluation of the Digital Rectal Examination as a Screening Test for Prostate CancerJNCI Journal of the National Cancer Institute, 1998
- Study of Prediagnostic Selenium Level in Toenails and the Risk of Advanced Prostate CancerJNCI Journal of the National Cancer Institute, 1998
- Decreased incidence of prostate cancer with selenium supplementation: results of a double‐blind cancer prevention trialBritish Journal of Urology, 1998
- Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the SkinJAMA, 1996
- Inhibitory effects of selenium on the growth of du-145 human prostate carcinoma cells in vitroBiochemical and Biophysical Research Communications, 1985
- PREDIAGNOSTIC SERUM SELENIUM AND RISK OF CANCERThe Lancet, 1983